Egyptian Journal of Cancer and Biomedical Research (EJCBR: https://jcbr.journals.ekb.eg/) is a publication of the Egyptian Association for Cancer Research (EACR; https://jcbr.journals.ekb.eg/). EJCBR, previously known as International Journal of Cancer and Biomedical Research (IJCBR) is a peer-reviewed online journal published quarterly. The first issue was published in December 2017. The journal allows free access (Open Access) to its contents and permits authors to self-archive a final accepted version of the articles on any OAI-compliant institutional/subject-based repository. EJCBR is indexed in Google Scholar, CAS, Crossref, …

Copyright and Licensing:

The policy for copyright shall be clearly stated in the author guidelines and in the copyright, holder named on all published articles. Likewise, licensing information shall be clearly described in guidelines on the website, and licensing terms shall be indicated on all published articles, both HTML and PDFs. If authors are allowed to publish under a Creative Commons license, then any specific license requirements shall be noted. Any policies on posting final accepted versions or published articles on third-party repositories shall be clearly stated.

An electronic backup and preservation of access to the journal content in the event the journal is suspended or no longer published is already available on the EKB (Egyptian Knowledge Bank) website (https://jcbr.journals.ekb.eg/). 

Copyright policy:

The journal allows the author(s) to hold the copyright, and to retain publishing rights without any restrictions.

Open access:

The journal is an open-access journal. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles under the following conditions: https://creativecommons.org/licenses/by/4.0/

For more information:

This work is licensed under https://creativecommons.org/licenses/by/4.0/

Plagiarism:
The journal has a strict policy against plagiarism. All submitted manuscripts are checked for plagiarism using professional plagiarism-checking software (iThenticate®). Submitted manuscripts with an unacceptable similarity index (more than 15%) resulting from plagiarism are rejected immediately.